Literature DB >> 22252805

Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.

Cheryl A Stoddart1, Geneviève Nault, Sofiya A Galkina, Nathalie Bousquet-Gagnon, Dominique Bridon, Omar Quraishi.   

Abstract

PC-1505 is a C34 peptide derived from the heptad repeat 2 region of HIV-1 gp41 conjugated to human serum albumin for sustained in vivo activity. One single preexposure dose of PC-1505 reduced viral RNA in HIV-1-infected SCID-hu Thy/Liv mice by 3.3 log₁₀ and protected T cells from virus-mediated depletion. In contrast, a single preexposure dose of Truvada reduced viral RNA by only 0.8 log₁₀ and was substantially less effective in preventing T cell depletion.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22252805      PMCID： PMC3318323          DOI： 10.1128/AAC.05015-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

Authors:  C A Stoddart; M E Moreno; V D Linquist-Stepps; C Bare; M R Bogan; A Gobbi; R W Buckheit; J Bedard; R F Rando; J M McCune
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

Review 3.  A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).

Authors:  Roberto Manfredi; Sergio Sabbatani
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

4.  Synthesis and evaluation of insulin-human serum albumin conjugates.

Authors:  Karen Thibaudeau; Roger Léger; Xicai Huang; Martin Robitaille; Omar Quraishi; Chantal Soucy; Nathalie Bousquet-Gagnon; Pieter van Wyk; Véronique Paradis; Jean-Paul Castaigne; Dominique Bridon
Journal:  Bioconjug Chem       Date:  2005 Jul-Aug       Impact factor: 4.774

5.  Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates.

Authors:  Roger Léger; Martin Robitaille; Omar Quraishi; Elizabeth Denholm; Corinne Benquet; Julie Carette; Pieter van Wyk; Isabelle Pellerin; Nathalie Bousquet-Gagnon; Jean-Paul Castaigne; Dominique Bridon
Journal:  Bioorg Med Chem Lett       Date:  2003-10-20       Impact factor: 2.823

6.  Kringle 5 peptide-albumin conjugates with anti-migratory activity.

Authors:  Roger Léger; Corinne Benquet; Xicai Huang; Omar Quraishi; Pieter van Wyk; Dominique Bridon
Journal:  Bioorg Med Chem Lett       Date:  2004-02-23       Impact factor: 2.823

7.  Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.

Authors:  Cheryl A Stoddart; Geneviève Nault; Sofiya A Galkina; Karen Thibaudeau; Peter Bakis; Nathalie Bousquet-Gagnon; Martin Robitaille; Maryanne Bellomo; Véronique Paradis; Patricia Liscourt; Alexandra Lobach; Marie-Eve Rivard; Roger G Ptak; Marie K Mankowski; Dominique Bridon; Omar Quraishi
Journal:  J Biol Chem       Date:  2008-09-22       Impact factor: 5.157

8.  Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.

Authors:  Paul W Denton; John F Krisko; Daniel A Powell; Melissa Mathias; Youn Tae Kwak; Francisco Martinez-Torres; Wei Zou; Deborah A Payne; Jacob D Estes; J Victor Garcia
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

9.  Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.

Authors:  Paul W Denton; Jacob D Estes; Zhifeng Sun; Florence A Othieno; Bangdong L Wei; Anja K Wege; Daniel A Powell; Deborah Payne; Ashley T Haase; J Victor Garcia
Journal:  PLoS Med       Date:  2008-01-15       Impact factor: 11.069

10.  Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.

Authors:  Cheryl A Stoddart; Pheroze Joshi; Barbara Sloan; Jennifer C Bare; Philip C Smith; Graham P Allaway; Carl T Wild; David E Martin
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240
View more
  7 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 2.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

3.  Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor.

Authors:  Lihong Liu; Michael Wen; Qianqian Zhu; Jason T Kimata; Paul Zhou
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-07       Impact factor: 4.147

Review 4.  Studies of retroviral infection in humanized mice.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Virology       Date:  2015-02-11       Impact factor: 3.616

Review 5.  Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

6.  Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Authors:  Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Brian R Long; Ekaterina Maidji; Mary E Moreno; Jose M Rivera; Ukina R Sanford; Barbara Sloan; Witold Cieplak; Terri Wrin; Po-Ying Chan-Hui
Journal:  Virology       Date:  2014-06-25       Impact factor: 3.616

7.  Protection against SIV in Rhesus Macaques Using Albumin and CD4-Based Vector-Mediated Gene Transfer.

Authors:  Sergei Spitsin; Bruce C Schnepp; Mary J Connell; Tehui Liu; Christine M Dang; Vasiliki Pappa; Richard Tustin; Annemarie Kinder; Philip R Johnson; Steven D Douglas
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-08       Impact factor: 6.698
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.